ECSP14030742A - Proteínas del factor 21 de crecimiento del fibroblasto - Google Patents

Proteínas del factor 21 de crecimiento del fibroblasto

Info

Publication number
ECSP14030742A
ECSP14030742A ECIEPI201430742A ECPI201430742A ECSP14030742A EC SP14030742 A ECSP14030742 A EC SP14030742A EC IEPI201430742 A ECIEPI201430742 A EC IEPI201430742A EC PI201430742 A ECPI201430742 A EC PI201430742A EC SP14030742 A ECSP14030742 A EC SP14030742A
Authority
EC
Ecuador
Prior art keywords
proteins
growth factor
fibroblast growth
fgf21
dyslipidemia
Prior art date
Application number
ECIEPI201430742A
Other languages
English (en)
Inventor
Craig Duane Dickinson
Malgorzata Donata Gonciarz
David Albert Driver
Ryan James Darling
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48670814&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP14030742(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP14030742A publication Critical patent/ECSP14030742A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/813—Carrier is a saccharide
    • Y10S530/814—Cellulose or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a proteínas del factor 21 de crecimiento del fibroblasto humano (FGF21) farmacológicamente potentes y estables, composiciones farmacéuticas que comprenden las proteínas del FGF21, y métodos para tratar diabetes tipo 2, obesidad, dislipidemia, y/o síndrome metabólico usando tales proteínas.
ECIEPI201430742A 2012-06-11 2014-12-11 Proteínas del factor 21 de crecimiento del fibroblasto ECSP14030742A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261658104P 2012-06-11 2012-06-11
US201361777386P 2013-03-12 2013-03-12

Publications (1)

Publication Number Publication Date
ECSP14030742A true ECSP14030742A (es) 2015-09-30

Family

ID=48670814

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201430742A ECSP14030742A (es) 2012-06-11 2014-12-11 Proteínas del factor 21 de crecimiento del fibroblasto

Country Status (24)

Country Link
US (2) US8741841B2 (es)
EP (1) EP2858662B1 (es)
JP (1) JP6182600B2 (es)
KR (1) KR20150006060A (es)
CN (1) CN104394882B (es)
AR (1) AR091216A1 (es)
AU (1) AU2013274638A1 (es)
BR (1) BR112014029966A2 (es)
CA (1) CA2871145A1 (es)
CL (1) CL2014003078A1 (es)
CO (1) CO7151525A2 (es)
EA (1) EA201492053A1 (es)
EC (1) ECSP14030742A (es)
ES (1) ES2644787T3 (es)
HK (1) HK1203357A1 (es)
IL (1) IL235832A0 (es)
IN (1) IN2014MN02132A (es)
MX (1) MX2014015257A (es)
PE (1) PE20150201A1 (es)
PH (1) PH12014502766A1 (es)
SG (1) SG11201408095XA (es)
TN (1) TN2014000439A1 (es)
TW (1) TWI513705B (es)
WO (1) WO2013188181A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008121563A2 (en) 2007-03-30 2008-10-09 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
WO2013006486A2 (en) 2011-07-01 2013-01-10 Ngm Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
EA201492064A1 (ru) * 2012-06-11 2015-02-27 Эли Лилли Энд Компани Варианты фактора роста фибробластов 21
TWI513705B (zh) 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
WO2014085365A2 (en) 2012-11-28 2014-06-05 Ngm Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CA2895517C (en) 2012-12-27 2022-10-11 Ngm Biopharmaceuticals, Inc. Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CN105828878A (zh) 2013-10-28 2016-08-03 恩格姆生物制药公司 癌症模型及相关方法
AU2015209131B2 (en) 2014-01-24 2020-06-25 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
EP3107937A4 (en) * 2014-02-21 2017-11-15 MedImmune, LLC Anti-pcsk9~glp-1 fusions and methods for use
JP6712230B2 (ja) 2014-03-11 2020-06-17 ノバルティス アーゲー リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法
CA2943355C (en) 2014-03-25 2023-09-05 Regeneron Pharmaceuticals, Inc. Fgf21 receptor agonists and uses thereof
WO2015183890A2 (en) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders and diseases
WO2015195509A2 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
JP6308699B2 (ja) * 2014-09-08 2018-04-11 国立大学法人大阪大学 脱髄疾患の予防又は治療剤
CA2964782A1 (en) 2014-10-23 2016-04-28 Ngm Biopharmaceuticals, Inc. Pharmaceutical compositions comprising peptide variants and methods of use thereof
EP3909596A1 (en) 2014-10-24 2021-11-17 Bristol-Myers Squibb Company Modified fgf-21 polypeptides and uses thereof
WO2016073855A1 (en) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
KR20160088656A (ko) * 2015-01-16 2016-07-26 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
US11638745B2 (en) 2015-05-20 2023-05-02 University of Pittsburgh—Of the Commonwealth Cvctom of Hierher Education Method to improve neurologic outcomes in temperature managed patients
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
KR102670157B1 (ko) 2015-10-28 2024-05-29 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
KR102668200B1 (ko) * 2015-10-28 2024-05-23 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
CA3082794A1 (en) 2015-11-09 2017-05-18 Ngm Biopharmaceuticals Inc. Methods for treatment of bile acid-related disorders
CN105348380B (zh) * 2015-12-28 2019-03-01 江苏康缘瑞翱生物医药科技有限公司 犬成纤维细胞生长因子21及其在治疗犬内分泌疾病中的用途
CN106317226B (zh) 2016-08-19 2017-09-05 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
US11123438B2 (en) 2016-08-19 2021-09-21 Ampsource Biopharma Shanghai Inc. Linker peptide for constructing fusion protein
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
WO2018039557A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
CA3042512A1 (en) 2016-11-10 2018-05-17 Yuhan Corporation Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins
JP7181886B2 (ja) 2017-03-14 2022-12-01 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 免疫グロブリンのＦｃ部分を含む二重標的融合タンパク質
EA201992516A1 (ru) 2017-04-21 2020-04-09 Юхан Корпорейшн Способ получения бифункциональных белков и их производных
CN107385020A (zh) * 2017-06-23 2017-11-24 西安医学院 瘦素在人重组fgf21蛋白活性检测中的应用
CA3072903A1 (en) 2017-09-08 2019-03-14 Bristol-Myers Squibb Company Modified fibroblast growth factor 21 (fgf-21) for use in methods for treating nonalcoholic steatohepatitis (nash)
CN110128525B (zh) 2018-02-08 2022-08-26 广东东阳光药业有限公司 Fgf21变体、融合蛋白及其应用
PE20210632A1 (es) 2018-07-03 2021-03-23 Bristol Myers Squibb Co Formulaciones de fgf-21
CN111195234B (zh) * 2018-11-16 2022-08-26 鲁南制药集团股份有限公司 一种重组FGF21-Fc融合蛋白冻干粉制剂
US20220064244A1 (en) * 2019-03-05 2022-03-03 Sunshine Lake Pharma Co., Ltd. A polypeptide molecule and application thereof
IL294534A (en) 2020-01-08 2022-09-01 Bristol Myers Squibb Co Formulations of fgf-21 conjugates
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
WO2022032187A1 (en) 2020-08-07 2022-02-10 Bristol-Myers Squibb Company Fgf21 combined with ccr2/5 antagonists for the treatment of fibrosis
KR20220021207A (ko) 2020-08-13 2022-02-22 주식회사 나이벡 이소골 형성 부작용 경감으로 치료효과가 증진된 골형성 단백질-9, 10의 변이체 및 이를 포함하는 약학적 조성물
KR102495299B1 (ko) * 2020-11-03 2023-02-06 토드제약 주식회사 Fgf21의 열탄력성을 이용한 fgf21 생산 방법
US20240123031A1 (en) 2020-11-25 2024-04-18 Bristol-Myers Squibb Company Methods of treating liver diseases
KR102631925B1 (ko) * 2021-06-10 2024-02-01 토드제약 주식회사 신규 fgf21 변이체 개발 및 이의 생산기법과 용도

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
AU2002322394A1 (en) 2001-07-30 2003-02-17 Eli Lilly And Company Method for treating diabetes and obesity
EA200601121A1 (ru) * 2003-12-10 2006-10-27 Эли Лилли Энд Компани Мутеины фактора роста фибробластов 21
EP2194064A1 (en) 2004-05-13 2010-06-09 Eli Lilly & Company FGF-21 fusion proteins
WO2008121563A2 (en) 2007-03-30 2008-10-09 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
JOP20190083A1 (ar) * 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
CH699521A2 (de) 2008-09-09 2010-03-15 Rotorcraft Ag Streckwerk für eine Strickmaschine.
JP5878757B2 (ja) 2008-10-10 2016-03-08 アムジエン・インコーポレーテツド Ｆｇｆ２１変異体およびその使用
WO2010065439A1 (en) 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
KR20110117666A (ko) 2009-01-23 2011-10-27 노보 노르디스크 에이/에스 알부민 바인더 ａ-ｂ-ｃ-ｄ-ｅ-를 갖는 ｆｇｆ21 유도체 및 그것의 사용
UY32607A (es) 2009-05-05 2010-12-31 Amgen Inc Mutantes de fgf21 y usos del mismo
MX2011011815A (es) 2009-05-05 2012-01-27 Amgen Inc Mutantes fgf21 y usos de los mismos.
JP2013533227A (ja) * 2010-06-08 2013-08-22 ノヴォ ノルディスク アー／エス Ｆｇｆ２１類似体および誘導体
AR087973A1 (es) * 2011-10-04 2014-04-30 Lilly Co Eli Variantes del factor 21 del crecimiento de fibroblastos
TWI513705B (zh) 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質

Also Published As

Publication number Publication date
EP2858662A1 (en) 2015-04-15
US8741841B2 (en) 2014-06-03
CL2014003078A1 (es) 2015-02-27
CN104394882B (zh) 2016-06-22
CN104394882A (zh) 2015-03-04
KR20150006060A (ko) 2015-01-15
TWI513705B (zh) 2015-12-21
PH12014502766A1 (en) 2015-02-09
US20130330336A1 (en) 2013-12-12
JP6182600B2 (ja) 2017-08-16
IL235832A0 (en) 2015-01-29
MX2014015257A (es) 2015-03-05
EA201492053A1 (ru) 2015-02-27
IN2014MN02132A (es) 2015-09-11
CA2871145A1 (en) 2013-12-19
PE20150201A1 (es) 2015-02-19
JP2015527974A (ja) 2015-09-24
AU2013274638A1 (en) 2014-11-06
HK1203357A1 (en) 2015-10-30
US20140228282A1 (en) 2014-08-14
AR091216A1 (es) 2015-01-21
BR112014029966A2 (pt) 2017-09-12
CO7151525A2 (es) 2014-12-29
EP2858662B1 (en) 2017-08-09
WO2013188181A1 (en) 2013-12-19
TN2014000439A1 (en) 2016-03-30
US8927492B2 (en) 2015-01-06
TW201408693A (zh) 2014-03-01
ES2644787T3 (es) 2017-11-30
SG11201408095XA (en) 2015-01-29

Similar Documents

Publication Publication Date Title
ECSP14030742A (es) Proteínas del factor 21 de crecimiento del fibroblasto
CR20140142A (es) Variantes delfactor 21 del crecimiento de fibroblastos
UY39119A (es) Proteínas de fusión para tratar trastornos metabólicos
MX2014015258A (es) Variantes del factor 21 de crecimiento de fibroblasto.
GT201300131A (es) Metodos de tratamiento de trastornos asociados con el fgf21
CR20150149A (es) Proteínas de fusión para el tratamiento de un síndrome metabólico
EA201491856A1 (ru) Терапевтическое применение белков фактора роста фибробластов 21
UY34859A (es) Análogos peptídicos de la exendina 4.
ECSP13012573A (es) 6-amino-nicotinamidas sustituidas como moduladores de KCNQ2/3
ECSP13012453A (es) 2-oxi-quinolina-3-carboxamidas sustituidas como moduladores KCNQ2/3
EA201590782A1 (ru) Оксирановые амины
UA112981C2 (uk) Варіант людського gdnf